PMID- 19835972
OWN - NLM
STAT- MEDLINE
DCOM- 20100528
LR  - 20220317
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Linking)
VI  - 16
IP  - 3
DP  - 2010 Mar
TI  - Partial T cell-depleted allogeneic stem cell transplantation following 
      reduced-intensity conditioning creates a platform for immunotherapy with donor 
      lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
PG  - 320-32
LID - 10.1016/j.bbmt.2009.10.006 [doi]
AB  - Allogeneic stem cell transplantation (SCT) in multiple myeloma (MM) may induce a 
      curative graft-versus-myeloma (GVM) effect. Major drawback in unmanipulated 
      reduced-intensity conditioning (RIC) SCT is the risk of severe and longstanding 
      graft-versus-host-disease (GVHD). This study demonstrates that transplantation 
      with a partial T cell-depleted graft creates a platform for boosting GVM immunity 
      by preemptive donor lymphocyte infusion (DLI) and recipient dendritic cell (DC) 
      vaccination, with limited GVHD. All 20MM patients engrafted successfully. 
      Chimerism analysis in 19 patients evaluable at 3 months revealed that 7 patients 
      were complete donor, whereas 12 patients were mixed chimeric. Grade II acute GVHD 
      (aGVHD) occurred in 7 patients (35%) and only 4 patients (21%) developed chronic 
      GVHD (cGVHD). Fourteen patients received posttransplantation immunotherapy, 8 
      preemptive DLI, 5 patients both DLI and DC vaccination, and 1 patient DC 
      vaccination only. DC vaccination was associated with limited toxicity, and none 
      of these patients developed GVHD. Importantly, overall treatment-related 
      mortality (TRM) at 1 year was low (10%). Moreover, the overall survival (OS) is 
      84% with median follow-up of 27 months, and none of the patients died from 
      progressive disease. These findings illustrate that this novel approach is 
      associated with limited GVHD and mortality, thus creating an ideal platform for 
      adjuvant immunotherapy.
CI  - Copyright (c) 2010 American Society for Blood and Marrow Transplantation. 
      Published by Elsevier Inc. All rights reserved.
FAU - Levenga, Henriette
AU  - Levenga H
AD  - Department of Hematology, Radboud University Nijmegen Medical Centre, Geert 
      Grooteplein 8, Nijmegen, The Netherlands. t.levenga@hemat.umcn.nl
FAU - Schaap, Nicolaas
AU  - Schaap N
FAU - Maas, Frans
AU  - Maas F
FAU - Esendam, Bennie
AU  - Esendam B
FAU - Fredrix, Hanny
AU  - Fredrix H
FAU - Greupink-Draaisma, Annelies
AU  - Greupink-Draaisma A
FAU - de Witte, Theo
AU  - de Witte T
FAU - Dolstra, Harry
AU  - Dolstra H
FAU - Raymakers, Reinier
AU  - Raymakers R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091014
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulin Light Chains)
RN  - 0 (Immunoglobulins)
RN  - 0 (M-proteins (Myeloma))
RN  - 9013-72-3 (Hemocyanins)
RN  - FV4Y0JO2CX (keyhole-limpet hemocyanin)
SB  - IM
MH  - Adult
MH  - Dendritic Cells/cytology/immunology/metabolism/*transplantation
MH  - Female
MH  - Graft Survival/immunology
MH  - Graft vs Host Disease/immunology/*prevention & control
MH  - Graft vs Tumor Effect/*immunology
MH  - HLA Antigens/genetics/immunology
MH  - Hematopoietic Stem Cell Transplantation/*methods/mortality
MH  - Hemocyanins/immunology
MH  - Humans
MH  - Immunoglobulin Light Chains/blood/immunology
MH  - Immunoglobulins/blood
MH  - Kaplan-Meier Estimate
MH  - Lymphocyte Activation/immunology
MH  - *Lymphocyte Depletion
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/blood/immunology/*therapy
MH  - Siblings
MH  - T-Lymphocyte Subsets/cytology/immunology
MH  - T-Lymphocytes/cytology/immunology/transplantation
MH  - Transplantation Chimera/immunology
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - *Vaccination/adverse effects
EDAT- 2009/10/20 06:00
MHDA- 2010/05/29 06:00
CRDT- 2009/10/20 06:00
PHST- 2009/06/04 00:00 [received]
PHST- 2009/10/07 00:00 [accepted]
PHST- 2009/10/20 06:00 [entrez]
PHST- 2009/10/20 06:00 [pubmed]
PHST- 2010/05/29 06:00 [medline]
AID - S1083-8791(09)00462-5 [pii]
AID - 10.1016/j.bbmt.2009.10.006 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2010 Mar;16(3):320-32. doi: 
      10.1016/j.bbmt.2009.10.006. Epub 2009 Oct 14.